The Global Cachexia Pathway: Module 2 Optimizing Supportive Care
This is a summary of a presentation by Dr. Eric Roeland, MD, FASCO, FAAHPM which you can find here. Before participating, please read our CME and disclosure information which can be found here.
This activity is supported by an independent medical educational grant from Pfizer. This online education program has been designed for for US Healthcare Professionals only.
Once Cachexia is Recognised: Act Early
Recognising cachexia is only the first step; intervention must begin alongside anticancer treatment rather than waiting for severe weight or functional decline. Do not wait for weight loss to exceed 10% before initiating supportive interventions.
One Syndrome, Multiple Simultaneous Drivers
Cachexia involves concurrent drivers that must be addressed together, not sequentially:
- Reduced food intake: Requires individualised dietary counselling, targeted energy/protein goals, and oral nutritional supplements when targets are missed.
- Nutrition-impact symptoms: Actively address early satiety, nausea, taste changes, constipation, pain, and barriers like pancreatic exocrine insufficiency.
- Systemic inflammation and catabolic drive: Effective anticancer therapy helps address this. Anti-inflammatory agents and omega-3 fatty acids remain low-certainty adjuncts tested within multimodal protocols.
- Inactivity and anabolic resistance: Counteract with progressive resistance training and aerobic activity matched to the patient's performance status.
A Practical Multimodal Supportive-Care Pathway
RECOGNISE → IDENTIFY DRIVERS → TREAT SYMPTOMS → NUTRITION + EXERCISE/REHABILITATION + APPROPRIATE PHARMACOLOGY → REASSESS
These components should operate in parallel rather than requiring completion of one before another begins.
Nutrition: Counselling First, Products Second
Nutrition matters, but feeding alone cannot fully reverse the muscle loss of cancer cachexia. Do not frame a lack of weight gain as patient failure.
- Individualised dietary counselling is the first-line nutritional intervention.
- Refer to a dietitian early to evaluate food access, cooking capacity, and caregiver support.
- Aim for explicit targets: approximately 25–30 kcal/kg/day of energy and roughly 1.5 g/kg/day of protein.
- Utilise oral nutritional supplements only when counselling alone does not meet targets, ensuring they supplement rather than displace meals.
- Enteral and parenteral nutrition are not routinely recommended and should be reserved for highly select cases with clear, time-limited goals.
Before Adding Calories, Ask Whether the Patient Can Absorb Them
Increasing intake will have limited benefit if the patient cannot adequately digest or absorb what they eat. For patients with pancreatic cancer, actively look for pancreatic exocrine insufficiency (PEI).
- Most patients do not volunteer symptoms and adapt by avoiding dietary fat.
- Screen for steatorrhoea, bloating, urgency, and cramping after fatty meals.
- Pancreatic enzyme replacement therapy (PERT) should be titrated to symptoms and administered with every meal and snack.
Exercise and Rehabilitation: Prescribe According to Functional Status
Consider progressive resistance training and aerobic activity as tolerated, supervised by physiotherapy or rehabilitation services where available. Screen carefully for safety risks before prescribing, including weight-bearing bone metastases, thrombocytopenia, severe anaemia, or uncontrolled pain and dyspnoea.
| Functional Status | Supportive Approach | Primary Goal |
|---|---|---|
| ECOG 0–1 | Progressive resistance + aerobic activity | Preserve lean mass and treatment tolerance |
| ECOG 2 | Maintenance loading + activities of daily living | Preserve independence |
| ECOG 3–4 | Symptom-directed movement and positioning | Comfort and dignity |
Pharmacological Management: Treat Symptoms First
Treat what is blocking intake (nausea, constipation, pain, oral candidiasis, taste changes, early satiety) before treating appetite. Layering an appetite stimulant over an untreated symptom will fail.
| Option | Potential Role | Important Limitations |
|---|---|---|
| Low-dose olanzapine | ASCO 2023 rapid update first-choice option; improved appetite and weight gain (>5%). | Requires monitoring for tolerability. |
| Progesterone analogues | Short trial for appetite and weight gain (e.g., Megestrol). | Weight gain is primarily fat, not lean mass; carries thromboembolic and oedema risks. |
| Corticosteroids | Rapid appetite effect. | Effects wane within weeks; prolonged use accelerates muscle catabolism. |
| Mirtazapine | Antidepressant sometimes used off-label. | No better than placebo in cited randomised trial. |
| Anamorelin | Ghrelin receptor agonist approved in Japan for specific indications. | Not FDA approved; EMA marketing authorisation was refused. |
| Investigational | E.g., Anti-GDF-15 antibodies (ponsegromab). | Not commercially available; remains investigational. |
What Does the Multimodal Evidence Actually Show?
The MENAC Trial Snapshot:
- Intervention: Multimodal (nutritional counselling, fish oil, home-based exercise, anti-inflammatory medication) plus standard care vs standard care alone.
- Results: The multimodal approach stabilised weight (+0.05 kg vs -0.99 kg) at 6 weeks.
- Limitations: There was no significant difference in muscle mass or physical activity levels between groups.
- Takeaway: Multimodal care is feasible and prevents further weight loss, but it is a platform for targeted agents rather than a complete solution for restoring muscle mass.
Make Multimodal Care Routine: Who Does What?
These disciplines must be integrated early to be effective.
| Discipline | Key Responsibilities |
|---|---|
| Oncologist / APP / Nurse | Own the diagnosis, maintain cachexia on the problem list, and trigger supportive interventions. |
| Dietitian | Provide individualised counselling, set nutritional targets, and reassess actual intake. |
| Physiotherapy / Rehab | Prescribe resistance/aerobic activities matched to functional status and goals. |
| Pharmacist / Palliative | Manage symptoms, review medication burdens, and direct appropriate appetite pharmacology. |
Three Things to Change in Clinic Tomorrow
- 1. Refer at diagnosis, not at 10% weight loss. The window for effective intervention closes while waiting for an arbitrary threshold of deterioration.
- 2. Prescribe the levers together. Address nutrition, exercise, inflammation, and symptoms simultaneously in parallel, not sequentially.
- 3. Treat the symptom before the appetite. Prescribing an appetite stimulant without addressing underlying barriers to intake (like nausea or constipation) will not succeed.
References
- Muscaritoli M, et al. ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr. 2021;40(5):2898–2913.
- Roeland EJ, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol. 2020;38(21):2438–2453.
- Roeland EJ, et al. Cancer cachexia: ASCO guideline rapid recommendation update. J Clin Oncol. 2023;41(25):4178–4179.
- Arends J, et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines. ESMO Open. 2021;6(3):100092.
- Solheim TS, et al. Results from a randomised, open-label trial of a multimodal intervention (exercise, nutrition and anti-inflammatory medication) plus standard care versus standard care alone to attenuate cachexia in patients with advanced cancer undergoing chemotherapy. J Clin Oncol. 2024;42(17_suppl):LBA12007.
Content is accurate as of the date of release.
Content is accurate as of the date of release.